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Abstract
Introduction: Patients with incidental pT2-T3 gallbladder cancer (IGC) after a cholecystectomy may
benefit from a radical re-resection although their optimal treatment strategy is not well defined. In this
Unit, such patients undergo delayed staging at 3 months after a cholecystectomy to assess the evidence
of a residual tumour, extra hepatic spread and the biological behaviour of the tumour. The aim of this study
was to evaluate the outcome of patients who had delayed staging at 3 months after a cholecystectomy.
Methods: From July 2003 to July 2011, 56 patients with T2-T3 gallbladder cancer were referred to this
Unit of which 49 were diagnosed incidentally on histology after a cholecystectomy. All 49 patients
underwent delayed pre-operative staging using multi-detector computed tomography (MDCT) followed
selectively by laparoscopy at 3 months after a cholecystectomy. Data were collected from a prospectively
held database. The peri-operative and long-term outcomes of patients were analysed. SPSS software
was used for statistical analysis.
Results: There were 38 pT2 and 11 pT3 tumours. After delayed staging, 24/49 (49%) patients underwent
a radical resection, 24/49 (49%) were found to be inoperable on pre-operative assessment and 1/49 (2%)
patient underwent an exploratory laparotomy and were found to be unresectable. The overall median
survival from referral was 20.7 months (54.8 months for the group who had a radical re-resection versus
9.7 months for the group who had unresectable disease, P < 0.001). These results compare favourably
with the reported outcome of fast-track management for incidental pT2-T3 gallbladder cancer from other
major series in the literature.
Conclusion: Delayed staging in patients with incidental T2-T3 gallbladder cancer after a cholecystec-
tomy is a useful strategy to select patients who will benefit from a resection and avoid unnecessary major
surgery.
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Introduction
Incidental gallbladder cancer (IGC) is discovered in 0.3–2% of all
cholecystectomies.1 Up to 75% of patients with GC are unresect-
able at diagnosis and the 5-year survival is very poor (3–13%),
with a median survival of 3 to 11 months.2 If IGC is diagnosed at
an early enough stage, patients may benefit from a radical resec-
tion, with some encouraging results.3–5
T2IGC (a tumour involving the perimuscular connective
tissue)6) may have several implications: first, the tumour may have
been breached during the operation causing a potential peritoneal
dissemination; second, microscopic residual disease might be left
behind during the cholecystectomy resulting in a final tumour
stage being underestimated; finally, the aggressiveness of the
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tumour remains unknown. For these reasons, inoperable disease
may be found in a large number of patients with IGC at
laparotomy7–9 and a high percentage of patients undergoing a
radical resection will experience early metastatic diseases and poor
long-term survival.10
In order to minimize unnecessary surgery, a protocol of delayed
restaging prior to re-resection was adopted: those patients pre-
senting with IGC staged T2 or above after a cholecystectomy were
assessed at 3 months by a multi-detector computed tomography
(MDCT) scan followed selectively by laparoscopic staging before
being offered a radical resection.
The aim of this study was to retrospectively review the impact
of delayed restaging on the resectability rate, laparotomies for
unresectable disease and long-term survival in T2-T3 IGC
patients.
Methods
The Hepato-Pancreato-Biliary (HPB) Surgery Unit at Freeman
Hospital is a referral centre in the UK for HPB malignancies. Data
of patients with GC referred for further treatment are collected in
a prospectively maintained database and they include: demo-
graphics, histopathology of the initial cholecystectomy (including
completeness of a resection and gallbladder disruption at the
initial operation), operation data and follow-up.
All patients referred to our centre with a gallbladder mass from
May 2003 to July 2011 were considered. All cases were discussed in
a multidisciplinary meeting (MDM) with dedicated specialists.
Tumours were staged according to the 6th edition of AJCC/UICC
TNM system.11 Inoperability was defined by the presence of meta-
static disease (including lymphadenopathy beyond the hepa-
toduodenal ligament) or local infiltration of the main vascular
structures (portal vein and hepatic artery).
Once the diagnosis of resectable gallbladder cancer is con-
firmed, patients are seen in the outpatient clinic and if they are fit
and willing for a radical re-resection, an MDCT scan is organized
at 3 months after a cholecystectomy to restage disease prior to
re-exploration. The staging CT scan is reviewed again in the
MDM by dedicated radiologists before proceeding with a radical
resection or laparoscopy. Indications for a laparoscopy include
high-risk pathological and imaging findings, or biopsy of unde-
termined lesions. All laparoscopies are done as separate proce-
dures prior to a laparotomy and include inspection of the
peritoneal cavity and intra-operative ultrasound of the liver and
porta hepatis.
Statistical analysis
Comparison of demographic details and clinical characteristics
between the two groups was performed using Fisher’s exact tests
and the linear-by-linear chi-square. For means in the case of con-
tinuous numeric data, we used the independent samples t-test and
the Mann–Whitney U-test, respectively, for data normally and
non-normally distributed; the data were previously tested for nor-
mality by the Kolmogorov–Smirnov test. Survival was estimated
using Kaplan–Meier analysis. A two-tailed P-value less than 0.05
was considered significant. SPSS 19.0 (SPSS, Chicago, IL, USA)
was used for statistical analysis.
Results
Two-hundred and seventy patients with presumed GC were
referred to this Unit during the study time. IGC was diagnosed in
56 patients. Seven patients were not offered any further treatment:
five pT1 and two pT2 patients were unfit for surgery. Forty-nine
patients with incidental pT2-T3 GC who were considered for
re-exploration were included in this analysis. Patients’ character-
istics are summarized in Table 1. There were 20 (40.8%) men and
29 (51.2%) women with a median age of 64.4 years (range 48–85).
Twenty-four patients (49%) had an incomplete resection at chole-
cystectomy. Evidence of residual disease was found in 49% of the
cholecystectomy specimens, and gallbladder disruption at chole-
cystectomy was recorded in 59% of the cases. There were no
cases of a positive margin on the cystic duct at the initial
cholecystectomy.
According to our staging protocol, 24 (49%) patients under-
went a radical re-resection and 25 (51%) were deemed to be
inoperable at 3-months staging. An algorithm of delayed restaging
is shown in Fig. 1.
No patients refused surgery. The rationale of the delay was
explained to all patients and none requested early surgery.
Inoperability findings were peritoneal disease only (n = 7), liver
metastases (n = 7), combined liver and peritoneal metastases (n =
1), vascular involvement (n = 2), lymph nodes metastases (3),
combined hilar mass and peritoneal metastases (n = 1), combined
hilar mass and liver metastases (n = 2), lymph nodes and distant
metastases (1) and combined liver and distant metastases (n = 1).
Table 1 Patients' characteristics
Age at referral years,
median (range)
64.3 (48–85)
Gender
• M 20 (40.8%)
• F 29 (51.2%)
T at referral
• T2 37
• T3 12
R + * 24 (49%)
Grading**
• 1 19
• 2 20
• 3 9
Specimen disruption 29 (59%)
*Residual disease at cholecystectomy; **Adenocarcinoma only.
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One of the 25 inoperable patients was diagnosed with metastatic
nodal disease at exploratory laparotomy.
Twenty-two patients received a segment 4b-5 resection with a
lymphadenectomy of the hepatic pedicle, and 16 out of these 22
patients underwent a resection of the extrahepatic biliary tree. A
major hepatectomy (>4 segments) with resection of the extrahe-
patic biliary tree was performed in the remaining two cases.
At final histology, evidence of a tumour on the final specimen
was demonstrated in 10 patients. Six patients had liver invasion,
three patients had liver invasion and lymph node metastasis and
one patient had lymph node metastasis only. None of the patients
had final involvement of the bile duct. Amongst the nine patients
with liver invasion, four had a positive margin at the time of the
initial cholecystectomy. The rationale for bile duct removal was
based on an intra-operative suspicion of bile duct involvement.
None of the patients had final involvement of the bile duct.
The complication and mortality rate were 21% (5 patients) and
4% (1 patient), respectively. Post-operative histology showed a
pT and pN upgrade in three (12.5%) and five (21%) cases. Six
patients received an R1 resection (25%). The median survival was
20.7 months (54.8 months for resectable patients versus 9.7
months for unresectable patients, P < 0.001) (Fig. 2).
Discussion
Encouraging results have been reported from tertiary centres per-
forming very aggressive surgery for incidental pT2-T3 GB and
acceptable survival can be achieved when the lymph node status is
negative.3,12–15
In this study, it was demonstrated that an acceptable 5-year
survival can be obtained delaying the staging before a radical
resection. This can result in a more accurate patient selection and
a reduction in the number of exploratory laparotomies. When
comparing our results with other major series (Table 2), a very
good median survival for those patients who received a radical
surgery and who were selected for having less aggressive disease
was observed. This would obviously imply a lower resection rate,
considering that we did not have any T4 tumours in the series.
Centres that use a more aggressive approach might consider our
protocol too selective. However, even in these studies it is clear that
many post-cholecystectomy pT2-T3 patients will not have a good
outcome. Fong et al. in their series of pT2-T4 IGB patients showed
that:
1 nearly half of the initial group of patients did not receive radical
surgery because of inoperability at restaging or because of
intra-operative findings;
2 some more patients were unfit for radical surgery and were
therefore not referred or not considered;
3 the mortality rate was approximately 4%;
4 the percentage of lymph node metastasis was very high, and the
5-year survival rate for AJCC stage III (N1) is lower than 10%;
and
5 some patients had R1 resections
Ultimately, patient selection is very important to achieve a good
outcome. In spite of rigorous staging with cross-sectional imag-
ing and laparoscopy, disseminated disease is diagnosed at re-
exploration in 24–60.3% of cases and an exploratory laparotomy
should be carefully avoided in these patients as it has a negative
impact on survival.15,16
In this institution, a radical re-resection is offered to all patients
with pT2-T3 GC diagnosed after a cholecystectomy who are medi-
cally fit. An agreed delayed restaging approach prior to
re-exploration allows us to consider the likelihood of tumour
violation at cholecystectomy, a planed ‘test of time’, avoiding
surgery on patients with microscopic peritoneal dissemination
and aggressive disease. This last issue seems to be increasingly
important and in fact some authors are now questioning the
utility of aggressive surgery in GC17–19
The choice of a 3-months’ time frame was essentially based on
an estimation that a tumour would require to show up on a
follow-up scan. This time frame is what Radiologists usually rec-
ommend to follow-up undetermined nodules or discover tumour
recurrence at intensive follow-up and it has been previously vali-
dated in other studies.20 In addition, the two senior authors based
the 3 months on a personal experience of re-operating within 6
weeks and found an unacceptable incidence of ‘open and close’ as
a result of peritoneal metastases.
The interpretation of a delayed CT scan by a specialist radiolo-
gist and the discussion of every single case in a multidisciplinary
meeting with dedicated specialists, have of course contributed to
increase the accuracy of our patients selection. A laparoscopy was
done selectively in the present patients and proved a useful means
to obtain a tissue diagnosis in inoperable patients (n = 11) with the
Figure 1 Algorithm of the delayed restaging protocol
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view of palliative treatment but did not alter the management in
any of the patients with a provisional diagnosis of operable disease
on CT (n = 9).
This study has several limitations: first, it is a retrospective study
and although the data have been collected from a prospectively
held database, many patients have been referred from other
centres. Second, the lack of a control group makes it very difficult
to compare this protocol with a more aggressive approach. On the
other hand, given the small sample size even for national referral
centres, it would be very difficult to design a prospective study.
Unfortunately historical data are not available for comparison as
this study backdates to the beginning of HPB centralization in the
UK, and that is why we can only compare our data with other
authors’ experiences. Given the small number of patients present-
ing with this disease, a control arm would require a much longer
recruitment time for a single-centre study.
In conclusion, this study attempts to address the impact of
timing in the selection process for a radical re-resection in patients
with a pT2-T3 gallbladder diagnosed after a cholecystectomy. The
present results show that delayed restaging minimizes exploratory
laparotomies without apparently affecting the outcome. Further
multicentre studies are needed to confirm our findings.
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